Thereafter, we screened different senolytic drugs and have identified the B-cell lymphoma-extra large (BCL-XL) inhibitor, A1155463, as the most promising molecule to eliminate specifically senescent myoblasts cultured from DM1 patients’ samples, without affecting cells cultured from healthy controls’ samples. This evidence concerns the gene BCL2L1 and myotonic dystrophy type 1.